1-866-598-7166

After Surgery (Adjuvant) Treatment Trials

A Study of V940 (Cancer Vaccine) and Pembrolizumab After Surgery for Clear Cell and Papillary Kidney Cancer (INTerpath-004)

[vc_row][vc_column][vc_column_text css=""] Background: Intismeran autogene (V940/mRNA-4157) is a personalized cancer vaccine made using mRNA technology, designed to help the immune system recognize and fight the patient’s specific cancer. Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works...

Kidney Cancer Canada